Clinical and laboratory evaluation of the myeloprotective effect of medroxyprogesterone acetate in head and neck cancer

Amadori, Dino; Frassineti, Giovanni Luca; Flamini, Emanuela; Falcini, Fabio; Maltoni, Marco; Nanni, Oriana; Riccobon, Angela; Piccinini, Claudia

doi:10.1016/0959-8049(92)90511-y

Cited by 13 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This inhibitory effect was similar in all protocols where MPA was used: MPA for 2 months prior MNU (group 4), MPA for 2 months (group 5) or throughout (group 6) after MNU or MNU injected in MPA-treated mice (group 3). Only very few mammary tumors appeared in MNU-MPA treated animals of groups 3 and 4 and a that MPA reduces the bone marrow toxicity induced by antitumor drugs [4]. Studies are needed to discriminate whether it is the progestagenic or the glucocorticoid effects of MPA the one that is playing this protective role.…”

Section: Resultsmentioning

confidence: 99%

“…It has been reported that patients receiving chemotherapy and MPA display a better general clinic state and that this drug is an important aid towards improving the quality of life of patients with either hormone-sensitive or hormone-insensitive tumors. These observations suggested that the analgesic and anabolic actions of MPA could be responsible of these effects [2] and that MPA might be myeloprotective [4].…”

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Protective role of medroxyprogesterone acetate on N-methyl-N-nitrosourea-induced lymphomas in BALB/c female mice

2001

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 96%

Protective role of medroxyprogesterone acetate on N-methyl-N-nitrosourea-induced lymphomas in BALB/c female mice

2001

View full text Add to dashboard Cite

“…Some clinical studies have demonstrated that highdose MPA might reduce hematologic toxicity in patients receiving chemotherapy for solid tumors [1][2][3]. It was shown in vitro and in vivo that secretion and synthesis of cytokines like IL-1, IL-6 and tumor necrosis factor (TNF), which play a role in the pathogenesis of cancer-related anorexia/cachexia, could be downregulated by MPA [12].…”

Section: Discussionmentioning

confidence: 99%

“…In addition to its wellknown effect, some clinical studies have demonstrated that high-dose MPA might reduce hematological toxicity in patients receiving chemotherapy for solid tumors [1][2][3]. The underlying mechanism of this action is still unknown.…”

Section: Introductionmentioning

confidence: 99%

“…A direct effect of MPA on hemopoietic cells has been postulated, but in vitro studies have showed contradictory results. However, some studies have implied that the myeloprotective effect of MPA may be due to induction of a mitotic rest in the stem cells, which protects them from drug action [2,4,5]. However, there is no study showing the effects of MPA on CD34+ cells in vitro.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Effects of Medroxyprogesterone Acetate on Apoptosis of CD34+ Cells

Aydin

Özdemir²,

Kavgacı³

et al. 2003

Chemotherapy

View full text Add to dashboard Cite

Background: Medroxyprogesterone acetate (MPA) is widely used in oncology practice, especially in the treatment of gynecological malignancies and cachexia of cancer. Some studies have demonstrated that high-dose MPA might reduce hematological toxicity in patients receiving chemotherapy for solid tumors. The underlying mechanism of this action is still unknown. We aimed to investigate the in vitro effects of MPA on CD34+ cells. Methods: We investigated the in vitro effects of two different doses of MPA (10 and 100 ng/ml) on acidic pH-induced apoptosis of CD34+ cells derived from 12 healthy volunteers. Results: Compared with the control group, we found that MPA at the dose of 100 ng/ml has a negative effect on apoptosis (6.7 ± 3.8 and 12.5 ± 5.0% apoptosis, respectively; p = 0.038) and a positive effect on the number of CD34+ cells (680 ± 294 and 350 ± 131 × 10³/ml, respectively; p = 0.009). Conclusion: Our results indicate that further studies are needed on larger populations in order to assess the relationship between MPA and its myeloprotective effect.

show abstract

Chemohormone therapy of metastatic melanoma with megestrol acetate plus dacarbazine, carmustine, and cisplatin

Nathanson

Meelu

Losada

1994

Cancer

View full text Add to dashboard Cite

Background. Chemotherapy with dacarbazine, carmustine, and cisplatin produces a modest objective response rate in melanoma. Megestrol acetate may ameliorate cachexia, abrogate drug resistance, and increase survival time in melanoma. Methods. Nineteen patients with metastatic melanoma (16 evaluable) treated with dacarbazine (220 mg/ m2/day for 3 days, intravenously [IV]), cisplatin (25 mg/ m2/day for 3 days IV) every 3 weeks, and carmustine (150 mg/m2 IV single dose every 6 weeks) together with megestrol acetate (160 mg/day by mouth continuously) starting 2 days before chemotherapy. Results. This regimen was well tolerated and resulted in a mean net weight gain of 1.45 kg. A 47% objective response rate was observed in all patients, including visceral sites of response, with a 39+ week median duration of response and median survival time of 16.7+ months in all evaluable patients. Conclusions. In this small Phase II study, the authors showed that megestrol acetate may contribute to a high objective response rate and prolonged median survival when used with a chemotherapy regimen of dacarbazine, carmustine, and cisplatin.

show abstract

Clinical and laboratory evaluation of the myeloprotective effect of medroxyprogesterone acetate in head and neck cancer

Cited by 13 publications

References 18 publications

Protective role of medroxyprogesterone acetate on N-methyl-N-nitrosourea-induced lymphomas in BALB/c female mice

Protective role of medroxyprogesterone acetate on N-methyl-N-nitrosourea-induced lymphomas in BALB/c female mice

The Effects of Medroxyprogesterone Acetate on Apoptosis of CD34+ Cells

Chemohormone therapy of metastatic melanoma with megestrol acetate plus dacarbazine, carmustine, and cisplatin

Contact Info

Product

Resources

About